ABSTRACT
Acquired somatic mutations in hematopoietic stem and progenitor cells (clonal hematopoiesis or CH) are associated with advanced age, increased risk of cardiovascular and malignant diseases, and decreased overall survival.1–4 These adverse sequelae may be mediated by altered inflammatory profiles observed in patients with CH.2,5,6 A pro-inflammatory immunologic profile is also associated with worse outcomes of certain infections, including SARS-CoV-2 and its associated disease Covid-19.7,8 Whether CH predisposes to severe Covid-19 or other infections is unknown. Among 515 individuals with Covid-19 from Memorial Sloan Kettering (MSK) and the Korean Clonal Hematopoiesis (KoCH) consortia, we found that CH was associated with severe Covid-19 outcomes (OR=1.9, 95%=1.2-2.9, p=0.01). We further explored the relationship between CH and risk of other infections in 14,211 solid tumor patients at MSK. CH was significantly associated with risk of Clostridium Difficile (HR=2.0, 95% CI: 1.2-3.3, p=6×10−3) and Streptococcus/Enterococcus infections (HR=1.5, 95% CI=1.1-2.1, p=5×10−3). These findings suggest a relationship between CH and risk of severe infections that warrants further investigation.
Competing Interest Statement
The authors declare the following competing interests: K.B. has received research funding from GRAIL; Y.K is a co-founder in Genome Opinion. M.F.B is on the advisory board for Roche and recieves research support from Illumina. R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Loxo, Imago, C4 Therapeutics and Isoplexis which include equity interest. He receives research support from and consulted for Celgene and Roche and has consulted for Lilly, Janssen, Astellas, Morphosys and Novartis. He has received honoraria from Roche, Lilly and Amgen for invited lectures and from Gilead for grant reviews. A.Z. received honoraria from Illumina. E.P receives research funding from Celgene.D.G and has received honoraria for speaking and scientific advisory engagements with Celgene, Prime Oncology, Novartis, Illumina and Kyowa Hakko Kirin and is a co-founder in Isabl Technologies. M. Ladanyi serves on the advisory boards for AstraZeneca, Bristol Myers Squibb, Takeda, Bayer and Merck, and has received research support from Loxo Oncology and Helsinn Therapeutics. L.A.D. is a member of the board of directors of Personal Genome Diagnostics (PGDx) and Jounce Therapeutics; is a paid consultant to PGDx and Neophore; is an uncompensated consultant for Merck (with the exception of travel and research support for clinical trials); is an inventor of multiple licensed patents related to technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy from Johns Hopkins University, some of which are associated with equity or royalty payments directly to Johns Hopkins and L.A.D.; and holds equity in PGDx, Jounce Therapeutics, Thrive Earlier Detection and Neophore; his wife holds equity in Amgen. The terms of all of these arrangements are being managed by Johns Hopkins and Memorial Sloan Kettering in accordance with their conflict of interest policies. H.I, C.H.S, H.S, S.K are current employees of Genome Opinion and holds stock in the company.
Funding Statement
This work was supported by the National Institute of Health (K08CA241318 to K.L.B and P50 CA172012 to L.B) the American Society of Hematology (K.L.B) the EvansMDS Foundation (K.L.B.) the European Hematology Association (E.P.) the Gabrielle Angels Foundation (E.P.) the V Foundation (E.P.) the Geoffrey Beene Foundation (E.P) the Starr Cancer Consortium (to R.L. A.Z. M.B and R.P.) and the Cancer Colorectal Cancer Dream Team Translational Research Grant (SU2C-AACR-DT22-17 to L.D.). M.M is supported by funds from the Intramural Research Program of the National Cancer Institute at the National Institutes of Health. The KoCH cohort was supported through a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health and Welfare the Republic of Korea (grant number: HI14C1277). We thank the Global Science experimental Data hub Center (GSDC) and Korea Research Environment Open NETwork (KREONET) service for data computing and network provided by the Korea Institute of Science and Technology Information (KISTI). Work performed at Memorial Sloan Kettering Cancer Center was supported in part by the Cancer Center Support Grant (grant no. P30 CA008748) the Marie Jose and Henry R Kravis Center for Molecular Oncology the Cycle for Survival and the MSK Molecular Diagnostics Service.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Memorial Sloan Kettering (MSK) cohort included solid tumor patients who underwent matched tumor and blood sequencing using the MSK-IMPACT panel on an institutional prospective tumor sequencing protocol (ClinicalTrials.gov number, NCT01775072). This study was approved by the MSK IRB (IRB number 12-245). The KoCH cohort included laboratory-confirmed patients with Covid-19 between January and April 2020 in four tertiary hospitals in Republic of Korea, Seoul National University Hospital, Seoul National University Bundang Hospital, National Medical Center and Kyungpook National University Hospital. The Seoul National University Hospital IRB, Seoul National University Bundang Hospital IRB, National Medical Center IRB and Kyungpook National University Hospital IRB approved the study (IRB numbers 2003-141-1110, B-2006/616-409, NMC-2008-050, KNUH-2020-04-069-001, respectively).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The minimal clinical and genetic data frame used to generate all analyses presented in this paper are available by request and will be made publicly available upon acceptance to a peer-reviewed journal.
